IDEXX Laboratories reported third‑quarter 2025 revenue of $1,105 million, up 13% from the same period last year and 12% on an organic basis. The quarter’s earnings per share were $3.40, beating the consensus estimate of $3.14 and the prior year’s Q3 EPS of $2.80.
The Companion Animal Group drove the majority of growth, reporting a 14% increase in revenue and 12% organic growth. The Livestock, Poultry and Dairy segment grew 17% year‑over‑year and 14% organically, reflecting strong demand for diagnostic services across the animal health market.
IDEXX raised its full‑year revenue guidance to $4,280 million, up from the previous $4,205‑$4,280 million range, and lifted its earnings per share outlook to $12.76, above the prior $12.40‑$12.76 range. The company cited continued adoption of its inVue Dx™ analyzers, recurring revenue from consumables, and a robust pipeline of new diagnostic solutions as key drivers.
Management highlighted that the reported EPS included tax benefits from share‑based compensation and an increase in tax expense due to recent U.S. tax law changes. Currency fluctuations had a minor impact on the results. The company reaffirmed its confidence in sustained demand for veterinary diagnostics and its leadership position in the pet‑health market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.